Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has entered the Maintenance Phase of the double-blind trial, SP902, (ie, has taken at least 1 dose of SP902 Maintenance Phase trial medication) and either completed SP902 or met an exit criterion in SP902; subject is allowed up to 2 concomitant Antiepileptic Drugs (AEDs)~Exclusion Criteria:~* Subject meets the withdrawal criteria (excluding exit criteria) for the SP902 trial, or is experiencing an ongoing Serious Adverse Event (SAE)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Lacosamide tablets for dosing 100 -800 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).